INVIVO THERAPEUTICS HOLDINGS CORP.
CIK 0001292519
Revenue (TTM)
—
Q3 Nov 2023
Net Income (TTM)
−$9.72M
−6.0% YoY
Q3 Nov 2023
EPS Diluted (TTM)
−$6.74
+8.7% YoY
Q3 Nov 2023
Gross Margin
—
Q3 Nov 2023
Operating Margin
—
Q3 Nov 2023
Net Margin
—
Q3 Nov 2023
Free Cash Flow (TTM)
−$14.1M
Q3 Nov 2023
Cash
$8.58M
Q3 Nov 2023
Total Debt
—
Q3 Nov 2023
Shares Outstanding
3.11M sh
Q3 Nov 2023
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.